Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vacc-C5 + Alhydrogel
- Development stage
- Unknown
- Lead developer
- Bionor
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vacc-C5 + Alhydrogel is a combination of a therapeutic HIV vaccine candidate (Vacc-C5) and an adjuvant (Alhydrogel). Vacc-C5 is a synthetic peptide vaccine designed to target the C5 domain of the HIV-1 envelope glycoprotein gp120 and the external domain of gp41. The goal is to modulate immune hyperactivation in people living with HIV by inducing specific immune responses against these conserved regions. Alhydrogel, which consists of aluminum hydroxide gel, acts as an adjuvant to enhance the immunogenicity of Vacc-C5 by promoting antigen uptake and stimulating Th2-type immune responses. This combination has been evaluated in early-phase clinical trials for safety and immunogenicity in HIV-infected individuals[1][3][4].
- Other names
- aluminum hydroxide gelvacc-c5vacc-c-5vacc-c 5
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)gp120 C5 (HIV-1 gp120 C5 domain)
Beyond the preview
Go deeper on Vacc-C5 + Alhydrogel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vacc-C5 + Alhydrogel.